Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
3.250
-0.140 (-4.13%)
Sep 15, 2025, 4:00 PM EDT - Market closed
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $244.00K in the quarter ending June 30, 2025, with 190.48% growth. This brings the company's revenue in the last twelve months to $646.00K, down -33.47% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.
Revenue (ttm)
$646.00K
Revenue Growth
-33.47%
P/S Ratio
163.78
Revenue / Employee
$11,333
Employees
57
Market Cap
99.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
Mar 31, 2024 | 1.06M | 1.29M | -568.72% |
Mar 31, 2023 | -227.00K | -1.34M | -120.47% |
Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
Mar 31, 2021 | 1.09M | - | - |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VTGN News
- 6 days ago - Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - Business Wire
- 5 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - Business Wire
- 6 weeks ago - Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 - Business Wire
- 7 weeks ago - Vistagen to Present at the BTIG Virtual Biotechnology Conference - Business Wire
- 2 months ago - Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership - Business Wire
- 2 months ago - Vistagen Appoints Elissa Cote as Chief Corporate Development Officer - Business Wire
- 3 months ago - Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript - Seeking Alpha